CSPC Pharmaceutical Announces 2020 Interim Results
Profit Attributable To Shareholders Increased 23.2% to RMB2,314 Million Declared An Interim Dividend of HK6 Cents Per Share Proposed A Bonus Issue of 3 Bonus Shares For Every 5 Existing Shares Held HONG KONG, Aug. 26, 2020 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC P...
CSPC Pharmaceutical Announces 2019 Annual Results
Profit Attributable To Shareholders Increased 20.6% to RMB3,714 Million Innovative Drug Business Continued to Deliver Strong Growth New Products Launched Helped to Sustain Growth HONG KONG, March 30, 2020 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC Pharmaceutical" or the...
CSPC Pharmaceutical Announces 2019 Interim Results
Profit Attributable To Shareholders Increased 24.8% to RMB1,878 Million Innovative Drug Business Continued to Deliver Strong Growth R&D Investment Increased Significantly HONG KONG, Aug. 19, 2019 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC Pharmaceutical" or the "Group")...
CSPC Pharmaceutical Announces 2018 Annual Results
* Profit Attributable To Shareholders Increased 31.9% to HK$3,655 Million * Innovative Drug Business Continued to Deliver Strong Growth * R&D Deployment Further Improved HONG KONG, March 18, 2019 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC Pharmaceutical" or the "G...
CSPC Pharmaceutical Announces 2018 Interim Results
* Profit Attributable To Shareholders Increased 41.1% to HK$1,853 Million * Innovative Drug Business Continued to Deliver Strong Growth * Common Generic Drug Business Increased Market Penetration * Bulk Drug Business Kept Market Leader Position; R&D Deployment Further Improved HONG KONG,...
